166 related articles for article (PubMed ID: 28716895)
21. Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics.
Karpathiou G; Casteillo F; Giroult JB; Forest F; Fournel P; Monaya A; Froudarakis M; Dumollard JM; Prades JM; Peoc'h M
Oncotarget; 2017 Mar; 8(12):19310-19322. PubMed ID: 28038471
[TBL] [Abstract][Full Text] [Related]
22. B7-dependent T-cell costimulation in mice lacking CD28 and CTLA4.
Mandelbrot DA; Oosterwegel MA; Shimizu K; Yamada A; Freeman GJ; Mitchell RN; Sayegh MH; Sharpe AH
J Clin Invest; 2001 Apr; 107(7):881-7. PubMed ID: 11285307
[TBL] [Abstract][Full Text] [Related]
23. Sonodynamic therapy improves anti‑tumor immune effect by increasing the infiltration of CD8+ T cells and altering tumor blood vessels in murine B16F10 melanoma xenograft.
Peng Y; Jia L; Wang S; Cao W; Zheng J
Oncol Rep; 2018 Oct; 40(4):2163-2170. PubMed ID: 30106435
[TBL] [Abstract][Full Text] [Related]
24. The positive feedback loop of MAD2L1/TYK2/STAT3 induces progression in B-cell acute lymphoblastic leukaemia.
Zhu L; Li X; Liu D; Bai W; Yang H; Cheng Q; Xu L; Fang J
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6527-6540. PubMed ID: 36781502
[TBL] [Abstract][Full Text] [Related]
25. CTLA4-CD80/CD86 interactions on primary mouse CD4+ T cells integrate signal-strength information to modulate activation with Concanavalin A.
Mukherjee S; Ahmed A; Nandi D
J Leukoc Biol; 2005 Jul; 78(1):144-57. PubMed ID: 15788440
[TBL] [Abstract][Full Text] [Related]
26. Bruton's tyrosine kinase prevents activation of the anti-apoptotic transcription factor STAT3 and promotes apoptosis in neoplastic B-cells and B-cell precursors exposed to oxidative stress.
Uckun F; Ozer Z; Vassilev A
Br J Haematol; 2007 Feb; 136(4):574-89. PubMed ID: 17367410
[TBL] [Abstract][Full Text] [Related]
27. Expression of CD28 and CTLA4 on T cells in bone morrow of immune-mediated aplastic anemia mice.
Liu Z; Sun H; Liu W; Luo X; He L; Xu H
J Huazhong Univ Sci Technolog Med Sci; 2005; 25(5):508-9, 515. PubMed ID: 16463658
[TBL] [Abstract][Full Text] [Related]
28. Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.
Ahern E; Harjunpää H; Barkauskas D; Allen S; Takeda K; Yagita H; Wyld D; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2017 Oct; 23(19):5789-5801. PubMed ID: 28634284
[No Abstract] [Full Text] [Related]
29. Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphoma.
Ikeda S; Kitadate A; Ito M; Abe F; Nara M; Watanabe A; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2016 Mar; 7(12):13563-74. PubMed ID: 26789110
[TBL] [Abstract][Full Text] [Related]
30. CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model.
Yshii LM; Gebauer CM; Pignolet B; Mauré E; Quériault C; Pierau M; Saito H; Suzuki N; Brunner-Weinzierl M; Bauer J; Liblau R
Brain; 2016 Nov; 139(11):2923-2934. PubMed ID: 27604307
[TBL] [Abstract][Full Text] [Related]
31. CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.
Ren Z; Guo J; Liao J; Luan Y; Liu Z; Sun Z; Liu X; Liang Y; Peng H; Fu YX
Clin Cancer Res; 2017 Jan; 23(1):193-203. PubMed ID: 27354469
[TBL] [Abstract][Full Text] [Related]
32. SIRT6 inhibits growth of gastric cancer by inhibiting JAK2/STAT3 pathway.
Zhou J; Wu A; Yu X; Zhu J; Dai H
Oncol Rep; 2017 Aug; 38(2):1059-1066. PubMed ID: 28656307
[TBL] [Abstract][Full Text] [Related]
33. TGF-beta inhibits IL-12-induced activation of Jak-STAT pathway in T lymphocytes.
Bright JJ; Sriram S
J Immunol; 1998 Aug; 161(4):1772-7. PubMed ID: 9712043
[TBL] [Abstract][Full Text] [Related]
34. CTLA4-Ig preserves thymus-derived T regulatory cells.
Ahmadi SM; Hölzl MA; Mayer E; Wekerle T; Heitger A
Transplantation; 2014 Dec; 98(11):1158-64. PubMed ID: 25269023
[TBL] [Abstract][Full Text] [Related]
35. B7-H4(B7x)-Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients.
Yao Y; Ye H; Qi Z; Mo L; Yue Q; Baral A; Hoon DSB; Vera JC; Heiss JD; Chen CC; Zhang J; Jin K; Wang Y; Zang X; Mao Y; Zhou L
Clin Cancer Res; 2016 Jun; 22(11):2778-2790. PubMed ID: 27001312
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist.
Fife BT; Griffin MD; Abbas AK; Locksley RM; Bluestone JA
J Clin Invest; 2006 Aug; 116(8):2252-61. PubMed ID: 16886063
[TBL] [Abstract][Full Text] [Related]
37. [CTLA4-FasL protein for the prevention of immune rejection in mouse corneal transplantation].
Chen M; Shi WY; Wang FH; Xie LX
Zhonghua Yan Ke Za Zhi; 2008 Jan; 44(1):56-60. PubMed ID: 18510245
[TBL] [Abstract][Full Text] [Related]
38. JAK kinases overexpression promotes in vitro cell transformation.
Knoops L; Hornakova T; Royer Y; Constantinescu SN; Renauld JC
Oncogene; 2008 Mar; 27(11):1511-9. PubMed ID: 17873904
[TBL] [Abstract][Full Text] [Related]
39. Evidence that induction of tolerance in vivo involves active signaling via a B7 ligand-dependent mechanism: CTLA4-Ig protects V beta 8+ T cells from tolerance induction by the superantigen staphylococcal enterotoxin B.
Lane P; Haller C; McConnell F
Eur J Immunol; 1996 Apr; 26(4):858-62. PubMed ID: 8625979
[TBL] [Abstract][Full Text] [Related]
40. Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma.
Yoo HY; Kim P; Kim WS; Lee SH; Kim S; Kang SY; Jang HY; Lee JE; Kim J; Kim SJ; Ko YH; Lee S
Haematologica; 2016 Jun; 101(6):757-63. PubMed ID: 26819049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
